» Articles » PMID: 35443732

Glucose Metabolism and AD: Evidence for a Potential Diabetes Type 3

Overview
Date 2022 Apr 21
PMID 35443732
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Alzheimer's disease is the most prevalent cause of dementia in the elderly. Neuronal death and synaptic dysfunctions are considered the main hallmarks of this disease. The latter could be directly associated to an impaired metabolism. In particular, glucose metabolism impairment has demonstrated to be a key regulatory element in the onset and progression of AD, which is why nowadays AD is considered the type 3 diabetes.

Methods: We provide a thread regarding the influence of glucose metabolism in AD from three different perspectives: (i) as a regulator of the energy source, (ii) through several metabolic alterations, such as insulin resistance, that modify peripheral signaling pathways that influence activation of the immune system (e.g., insulin resistance, diabetes, etc.), and (iii) as modulators of various key post-translational modifications for protein aggregation, for example, influence on tau hyperphosphorylation and other important modifications, which determine its self-aggregating behavior and hence Alzheimer's pathogenesis.

Conclusions: In this revision, we observed a 3 edge-action in which glucose metabolism impairment is acting in the progression of AD: as blockade of energy source (e.g., mitochondrial dysfunction), through metabolic dysregulation and post-translational modifications in key proteins, such as tau. Therefore, the latter would sustain the current hypothesis that AD is, in fact, the novel diabetes type 3.

Citing Articles

Insufficient Sleep and Alzheimer's Disease: Potential Approach for Therapeutic Treatment Methods.

Trinh D, Mai N, Pham T Brain Sci. 2025; 15(1).

PMID: 39851389 PMC: 11763454. DOI: 10.3390/brainsci15010021.


Proteomic signatures of Alzheimer's disease and Lewy body dementias: A comparative analysis.

Canal-Garcia A, Branca R, Francis P, Ballard C, Winblad B, Lehtio J Alzheimers Dement. 2024; 21(1):e14375.

PMID: 39711511 PMC: 11780320. DOI: 10.1002/alz.14375.


Temporal changes of neurobehavior in rats following varied blast magnitudes and screening of serum biomarkers in early stage of brain injury.

Ma N, Wang H, Lu Q, Liu J, Fan X, Li L Sci Rep. 2024; 14(1):30023.

PMID: 39627295 PMC: 11615197. DOI: 10.1038/s41598-024-81656-9.


Alzheimer's Disease, Obesity, and Type 2 Diabetes: Focus on Common Neuroglial Dysfunctions (Critical Review and New Data on Human Brain and Models).

Toledano A, Rodriguez-Casado A, Alvarez M, Toledano-Diaz A Brain Sci. 2024; 14(11).

PMID: 39595866 PMC: 11591712. DOI: 10.3390/brainsci14111101.


Exploring diabesity pathophysiology through proteomic analysis using .

Subhadra M, Mir D, Ankita K, Sindunathy M, Kishore H, Ravichandiran V Front Endocrinol (Lausanne). 2024; 15:1383520.

PMID: 39539936 PMC: 11557309. DOI: 10.3389/fendo.2024.1383520.


References
1.
Park H, Kang J, Lee S . Autophagy in Neurodegenerative Diseases: A Hunter for Aggregates. Int J Mol Sci. 2020; 21(9). PMC: 7247013. DOI: 10.3390/ijms21093369. View

2.
Kullmann S, Heni M, Hallschmid M, Fritsche A, Preissl H, Haring H . Brain Insulin Resistance at the Crossroads of Metabolic and Cognitive Disorders in Humans. Physiol Rev. 2016; 96(4):1169-209. DOI: 10.1152/physrev.00032.2015. View

3.
Salameh T, Rhea E, Talbot K, Banks W . Brain uptake pharmacokinetics of incretin receptor agonists showing promise as Alzheimer's and Parkinson's disease therapeutics. Biochem Pharmacol. 2020; 180:114187. PMC: 7606641. DOI: 10.1016/j.bcp.2020.114187. View

4.
Liu F, Iqbal K, Grundke-Iqbal I, Hart G, Gong C . O-GlcNAcylation regulates phosphorylation of tau: a mechanism involved in Alzheimer's disease. Proc Natl Acad Sci U S A. 2004; 101(29):10804-9. PMC: 490015. DOI: 10.1073/pnas.0400348101. View

5.
Convit A, Wolf O, Tarshish C, de Leon M . Reduced glucose tolerance is associated with poor memory performance and hippocampal atrophy among normal elderly. Proc Natl Acad Sci U S A. 2003; 100(4):2019-22. PMC: 149951. DOI: 10.1073/pnas.0336073100. View